<DOC>
	<DOCNO>NCT01645293</DOCNO>
	<brief_summary>Patients cutaneous CD30 positive lymphoma receive systemical topical treatment genetically modify T cell . Treatment evaluation consist assessment safety preliminary evidence response .</brief_summary>
	<brief_title>Multicentre Phase I Trial Engineered T Cells Patients With Relapsed Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma Transformed CD30+ Mycosis Fungoides</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Lymphoma , Primary Cutaneous Anaplastic Large Cell</mesh_term>
	<criteria>Signed write informed consent , prior prestudy screen treatment , understanding consent may withdraw patient time without prejudice , ability understand write informed consent document . Male female &gt; 18 year age 70 year age Diagnosis primary cutaneous CD30+ large T cell lymphoma OR Diagnosis transform CD30+ mycosis fungoides , i.e. , Histological confirmation diagnosis . multiple ( &gt; 5 ) cutaneous tumor lesion ( TNM EORTC 2007 T3 , N1 , clinical stage &lt; IIb ) , Measurable disease accord RECIST criterion Refractory relapse disease least one line treatment , e.g . PUVA ( Psoralen plus UVA ) , PUVA + Interferon , oral Bexarotene , low dose MTX ) ECOG performance status 03 Life expectancy &gt; 12 month Female patient childbearing potential must negative serum pregnancy test within two week first dose study drug . Male female patient must agree use effective oral contraceptive method study treatment , appropriate , minimum twelve month follow study therapy Previously untreated patient Presence organ brain involvement determine tumor stag contrast compute tomography [ CT ] magnetic resonance image [ MRI ] scan Known hereditary blood coagulation disorders/DIC Prior allogeneic hematopoietic stemcell organ transplantation Severe cardiovascular disease like functionally restrict heart rhythm disturbance heart malformation severe hypertension , cardiac insufficiency &gt; NHYAII know active infection include HIV , Hepatitis B C , VZV , CMV Insufficient bone marrow reserve ( Leucocytes &lt; 3.500/μl ; Thrombocytes &lt; 100.000/μl ) CreatinineClearance &lt; 50 ml/min Crea &gt; 1.8 mg/dl Bilirubin &gt; 2 mg/dl ; ASAT , ALAT &gt; 2.5xN Pregnancy ( absence confirm serum/urine βHCG ) breastfeed Known pulmonary dysfunction Requirement chronic immune suppression Treatment corticosteroid concomitant intercurrent disease Having participate another clinical trial IND precede 4 week Anticancer chemotherapy precede 4 week Known drug abuse/alcohol abuse Known allergic/hypersensitivity reaction component treatment Known serious uncontrolled infection Known active secondary malignancy previous malignancy within 5 year , exception history previous basal cell carcinoma skin preinvasive carcinoma skin cervix Medical psychological condition inadequate knowledge german language opinion investigator would permit patient complete study meaningfully sign informed consent Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>